Clinical trials: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Condition Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Funder type Industry (pharma, biotech, devices)
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Chronic Inflammatory Demyelinating Polyneuropathy
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline.
- Trial name
- NCT01824251
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
- Trial name
- HERMOSA-2 (NCT07304154)
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 57 people
- Sponsor
- Kite, A Gilead Company
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to…
- Trial name
- NCT05327114
- Testing
- Nipocalimab
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is an extension study to the pivotal study IgPro20_3003 (NCT01545076). The purpose of this extension study is to investigate the long-term treatment of CIDP with IgPro20, with regard to safety and efficacy.
- Trial name
- NCT02027701
- Testing
- IgPro20
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 82 people
- Sponsor
- CSL Behring
Chronic Inflammatory Demyelinating Polyneuropathy
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP.
- Trial name
- INVGOR (NCT07027111)
- Testing
- NVG-2089
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nuvig Therapeutics, Inc.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)
A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal…
- Trial name
- NCT05084053
- Testing
- TAK-771
- Where
- 23 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Takeda
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of…
- Trial name
- NCT01545076
- Testing
- IgPro20 (low dose), IgPro10, IgPro20 (high dose)
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 208 people
- Sponsor
- CSL Behring
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- NCT04051944
- Testing
- Rozanolixizumab
- Where
- 14 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV).
- Trial name
- POINT (NCT01225276)
- Testing
- NewGam 10%
- Volunteers
- 2 people
- Sponsor
- Octapharma
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).
- Trial name
- NCT00099489
- Testing
- Interferon Beta-1a
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- Biogen
Healthy, Primary Immune Thrombocytopenia
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP).
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Trial name
- NCT03275740
- Testing
- PF-06755347 intravenous healthy participant, PF-06755347 subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and…
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Trial name
- NCT07264426
- Testing
- Efgartigimod PH20 SC
- Where
- 23 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Objectives: Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary…
- Trial name
- NCT04658472
- Testing
- SAR445088 (IV), SAR445088 (SC)
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 98 people
- Sponsor
- Bioverativ, a Sanofi company